Glenmark Pharma Quarterly Results

If you own Glenmark Pharma shares or are tracking the company, Q1 FY27 showed stronger business performance. Sales grew across India and major overseas markets.

• Revenue rose 23.1% to ₹4,018.48 crore
• PAT increased to about ₹482.8 crore
• EBITDA reached about ₹804.8 crore
• India business revenue grew 15.5% YoY
• North America revenue jumped 41.1% YoY
• Europe revenue increased 11.9% year-on-year

The quarter was stronger than the same period last year.

Glenmark Pharma's revenue from operations increased from ₹3,264.44 crore in Q1 FY26 to ₹4,018.48 crore in Q1 FY27. That is a 23.1% year-on-year rise.

Profit after tax, or PAT, increased from ₹46.97 crore to about ₹482.8 crore.

At first glance, that profit jump looks very large. But there is an important reason.

Last year's Q1 FY26 profit was hit by a ₹323.23 crore exceptional charge linked to U.S. litigation. This made the year-on-year profit comparison look much stronger in Q1 FY27.

So, do not look at PAT alone.

Yes, operating numbers also improved during the quarter.

Glenmark reported earnings before interest, tax, depreciation and amortisation, or EBITDA, of about ₹804.8 crore.

EBITDA grew around 38.6% year-on-year.

Its EBITDA margin was 20.03%, compared with roughly 17.8% in Q1 FY26.

This matters because EBITDA gives you a better idea of how the main business performed before some non-operating expenses.

What this means

Sales increased, operating profit grew faster than revenue, and margins improved.

But the jump in reported PAT looks unusually large because Q1 FY26 had a major litigation-related charge.

Glenmark's growth did not come from India alone.

Its major geographical businesses reported higher revenue in Q1 FY27.

India remained an important part of Glenmark's business.

North America showed the fastest reported growth among these regions.

However, there is one point you should not ignore.

North America revenue increased 41.1% year-on-year to ₹1,097.4 crore.

But this growth was not only from medicine sales.

The figure also included deferred out-licensing income linked to ISB 2001.

In simple words, part of the reported revenue came from a licensing arrangement rather than only regular product sales.

That is why future quarters should be compared carefully.

If licensing income reduces later, North America's growth rate can also look different.

Yes.

Glenmark's India formulations business reported revenue of ₹1,432.1 crore, up 15.5% year-on-year.

For an Indian investor, this number matters because it shows how Glenmark's domestic medicine business is performing.

India is also less dependent on the same factors affecting overseas markets, such as U.S. pricing pressure or foreign regulatory issues.

Still, one quarter alone cannot tell you whether 15.5% growth will continue.

Europe generated revenue of around ₹747.2 crore, up 11.9% year-on-year.

Emerging markets reported around ₹730.4 crore, up 27.7% year-on-year.

This means Glenmark saw double-digit growth in several major markets during the quarter.

For investors, broader growth can be useful to track because the company is not depending on only one geography for revenue.

There was no new Q1 FY27 interim dividend announcement linked to these quarterly results.

However, the company had declared an interim dividend of ₹2.50 per equity share for FY26.

This corrects the older statement that Glenmark had not declared any dividend during FY26.

A dividend should not be treated as guaranteed income. The amount and timing can change depending on company decisions and financial performance.

Glenmark announced its Q1 FY27 results on July 31, 2026.

Its share closed at around ₹2,233.30 that day, compared with the previous close of about ₹2,191.05.

That is a rise of roughly 1.9%.

But one day's price movement should not decide whether you buy, sell or hold a share.

Prices can move because of results, market mood, expectations and many other factors.

Suppose Ravi sees PAT rising from around ₹47 crore to ₹483 crore.

He may think, "Profit has increased ten times. The business must also have become ten times stronger."

That would be the wrong conclusion.

Part of the jump happened because Q1 FY26 had a ₹323.23 crore exceptional legal charge.

A better way is to check several numbers together:

• Revenue Growth: Is sales growth continuing?
• EBITDA Growth: Is operating profit improving?
• EBITDA Margin: Is the business earning better margins?
• India Growth: Is domestic demand staying strong?
• North America: How much income is recurring?
• Legal Costs: Are exceptional charges reducing?

Looking at these together gives you a clearer picture than looking at PAT alone.

The Q1 FY27 quarter ended on June 30, 2026.

After the quarter, Glenmark received an Establishment Inspection Report for its Goa manufacturing facility from the U.S. Food and Drug Administration.

The facility received a Voluntary Action Indicated, or VAI, classification following the June 2026 inspection.

This happened after the Q1 reporting period.

So, it should not be mixed with Q1 FY27 financial performance.

Glenmark's Q1 FY27 numbers were stronger than Q1 FY26 on revenue, EBITDA and PAT.

But the next few quarters will show whether the improvement can continue.

Keep an eye on:

• Margins staying near current levels
• India maintaining double-digit revenue growth
• Licensing income versus regular product sales
• North America sustaining business momentum
• Europe and emerging markets staying strong
• Future legal or regulatory developments

These points can help you understand whether the growth is becoming more consistent.

Glenmark Pharma reported a stronger Q1 FY27, with revenue rising 23.1% to ₹4,018.48 crore and EBITDA reaching about ₹804.8 crore. PAT increased sharply to about ₹482.8 crore, but the comparison benefited from a large legal charge in Q1 FY26.

For investors, the more useful signals are revenue growth, margins, regional performance and the share of recurring income. Checking these numbers over several quarters can give a clearer view of Glenmark Pharma's business performance.